Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julie Crouse

Registered Nurse, Emergency Fairfield, CA Nurse Practitioner

NPI 1457988016 CMS profile 10484867

1620 Pennsylvania Ave Ste C, Fairfield, CA 94533

Open in the dashboard

General payments

$3,724

175 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Crouse of Fairfield, CA is reported in the CMS Open Payments database as having received $3,724 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $822 35
2024 General $1,001 40
2023 General $861 40
2022 General $357 21
2021 General $685 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Crouse
  • Registered Nurse, Emergency median
  • Middle half of Registered Nurse, Emergency
  • National median

In program year 2025, general payments to Julie Crouse were reported at $822. Among 48 Registered Nurse, Emergency profiles paid that year, the median was $76 and the middle half received between $24 and $215.

Show as a table
Year Julie Crouse Registered Nurse, Emergency median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $685 — — $132
2022 $357 $56 $19–$124 $149
2023 $861 — — $160
2024 $1,001 $78 $25–$107 $164
2025 $822 $76 $24–$215 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $926 43 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $698 28 payments
  3. Novo Nordisk Inc $347 22 payments
  4. Lilly USA, LLC $247 12 payments
  5. Dexcom, Inc. $231 9 payments
  6. Amgen Inc. $198 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $120 6 payments
  8. Pfizer Inc. $113 6 payments
  9. Xeris Pharmaceuticals, Inc. $75 4 payments
  10. Astellas Pharma US Inc $75 3 payments
  11. Other $695 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,724 175 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $713 33 payments
  2. JARDIANCE Diabetes $349 12 payments
  3. RYBELSUS $333 21 payments
  4. Ozempic $264 17 payments
  5. UBRELVY $233 10 payments
  6. JARDIANCE Diabetes $231 12 payments
  7. Dexcom G6 Transmitter $231 9 payments
  8. Repatha $121 5 payments
  9. Otezla $121 5 payments
  10. Kerendia $120 6 payments
  11. Other $1,626 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

508

Median for Nurse Practitioner: 389

Drug cost

$46,665

Median for Nurse Practitioner: $21,885

Branded share of claims

14.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 17 $22,852
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $19,170
Rosuvastatin Calcium Generic 41 $783
Metformin Hcl Generic 56 $698
Levothyroxine Sodium Generic 58 $554
Atorvastatin Calcium Generic 51 $544
Lisinopril Generic 32 $249
Simvastatin Generic 24 $229
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $226
Duloxetine Hcl Generic 17 $178

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $327
$327 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $219
  • Lilly USA, LLC $17
$235 17 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $61
$61 — —
NURTEC ODT
  • PFIZER INC. $27
$27 — —
ZAVZPRET
  • PFIZER INC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Emergency in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record